Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01171092 · ClinicalTrials.gov registry record · Early Phase 1
A Safety Study Looking at the Combination of Velcade and G-CSF in Patients With Myeloma or Lymphoma
A Early Phase 1 study of Malignant Lymphoma, Stem Cell Type and Autologous Transplant, sponsored by University of Kansas Medical Center.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 21
- Enrollment target
- 2
- Study locations
NCT01171092 is a Early Phase 1 study of Malignant Lymphoma, Stem Cell Type and Autologous Transplant that has completed, run by University of Kansas Medical Center. The registered enrollment target is 21 participants. The trial reports 2 study locations across 1 state.
The verdict
NCT01171092, a Early Phase 1 study of Malignant Lymphoma, Stem Cell Type and Autologous Transplant, has completed, sponsored by University of Kansas Medical Center.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 21 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to determine if the combination of G-CSF and bortezomib is safe and effective in blood cell mobilization.
Conditions Studied
Interventions
- DRUG bortezomib and G-CSF
Study Locations (2)
Kansas
- University of Kansas Medical Center - Kansas City
- University of Kansas Medical Center, Westwood Campus - Westwood
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2010-09 |
| Est. Completion | 2014-12 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01171092
The ClinicalTrials.gov registry entry for NCT01171092 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Kansas Medical Center, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Malignant Lymphoma, Stem Cell Type appearing as the primary indexed condition, and to 1 intervention - of which bortezomib and G-CSF is the first listed.
NCT01171092 reports 2 study locations spanning 1 distinct geographic area - top geographies include Kansas.
Frequently Asked Questions
What is clinical trial NCT01171092 about?
NCT01171092 is a clinical study titled "A Safety Study Looking at the Combination of Velcade and G-CSF in Patients With Myeloma or Lymphoma". The purpose of this study is to determine if the combination of G-CSF and bortezomib is safe and effective in blood cell mobilization.
What is the current status of trial NCT01171092?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 21 participants. The study started on 2010-09. Estimated completion is 2014-12.
What conditions does trial NCT01171092 study?
This clinical trial studies the following conditions: Malignant Lymphoma, Stem Cell Type, Autologous Transplant.
What interventions are being tested in trial NCT01171092?
The interventions under investigation include: bortezomib and G-CSF (DRUG).
Who is sponsoring clinical trial NCT01171092?
This trial is sponsored by University of Kansas Medical Center, which has 408 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01171092 being conducted?
This trial has 2 study locations across Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.